Commentary: Not a “checkmate,” but great progress

Brendon M. Stiles, MD, and Marc Vimolratana, MD

Esophageal cancer continues to be one of our greatest surgical and oncologic challenges. Only a minority of patients will experience a complete pathologic response with combined chemotherapy and radiation therapy before surgery. Those patients with residual disease have recurrence rates as high as 70% to 75%. Although there has been progress in the neoadjuvant space, the adjuvant space has been notably barren of success stories. However, the recent publication of the CheckMate 577 trial and the subsequent approval by the Food and Drug Administration of adjuvant nivolumab is a game changer for patients with surgically resected esophageal/gastroesophageal cancer with complete resection but residual cancer.

Cameron and colleagues do an excellent job describing the CheckMate 577 trial and how it easily fits into the typical paradigm of treatment for these patients. The results of the trial were outstanding, with a 31% reduction (hazard ratio [HR], 0.69; confidence interval [CI], 0.56-0.86) in the risk of recurrence/death and a doubling of disease-free survival (DFS; 22.4 vs 11.0 months) for patients randomized to nivolumab. We agree that adjuvant nivolumab has little impact for surgeons on the perioperative care of their patients, making this approach quite attractive. The allowance of randomization up to 16 weeks after surgery allows patients the time to recover from the unique physiological challenges of esophagectomy. We also agree with the authors that the inclusion of patient-reported outcomes is critical in adjuvant trials. Improvements were seen from baseline scores and there were essentially no differences between patients receiving nivolumab and placebo. That, combined with the low rate of adverse events in the nivolumab arm, makes an easy case for patients.

Where we disagree a bit with the authors is on the “lack of dependency on PD-L1 expression” and the blanket “broad applicability.” Given the context of the approval from the Food and Drug Administration, nivolumab should certainly be considered for all eligible patients. However, although CheckMate 577 was stratified by tumor cell programmed death-ligand 1 expression, esophageal/gastric cancers are typically classified by the combined positive score (CPS), a measure of tumor and inflammatory cells. A post-hoc analysis showed that patients with a CPS of at least 5 (n = 371) had markedly improved DFS (HR, 0.62; CI, 0.46-0.83; median DFS, 29.4 vs 10.2 months vs placebo) compared with patients (n = 295) with CPS <5 (HR, 0.89; CI, 0.65-1.22; median DFS, 16.3 vs 11.1 months vs placebo). A similar dependence of response on CPS has been noted in the CheckMate 649 study in metastatic gastroesophageal cancer. Future studies are needed to better define biomarkers to identify subgroups of patients that will truly benefit from adjuvant nivolumab.

It is also important to note some of the caveats of any adjuvant approach. Outside of clinical trials, many patients don’t make it to or are unable to tolerate adjuvant therapy after esophagectomy. This is true even of healthier trial patients in the MAGIC (Medical Research Council...
Adjuvant Gastric Infusional Chemotherapy) and FLOT-4 (5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel) trials.\textsuperscript{4,5} Because CheckMate 577 only enrolled after tri-modality therapy was completed, we have no idea how many patients will drop out in the real world and not receive adjuvant nivolumab. A neoadjuvant immunotherapy approach may therefore be preferable, similar to CheckMate 816 in lung cancer.

Nevertheless, CheckMate 577 is a major breakthrough for patients with surgically resectable esophageal/gastro-esophageal junction cancer. With a host of ongoing trials as described by Cameron and colleagues, the pieces on the chessboard are moving rapidly. However, CheckMate 577 certainly gets us closer to the elusive endgame of cure for this deadly disease.

References